Phycin Inc engineers and manufactures next-generation growth factors, led by its Ultrastable™ basic fibroblast growth factor for regenerative medicine and advanced cell culture. Based in Frederick, Maryland, the company combines AI-guided protein engineering with a proprietary algae-based platform to produce animal-free, endotoxin-free growth factors. Its bFGF remains active for more than 21 days at 37°C and is designed to ease the storage and handling constraints of conventional products.
Algeline® (Reg. No. 6,103,131)
registration
Lifeline Cell TechnologyLifeline Cell Technology develops and manufactures purified primary human cells, stem-cell products, and optimized cell-culture media for laboratory research. Its founders helped introduce normal human cell systems more than 25 years ago, and the company now operates an 8,000-square-foot laboratory and administrative facility in Frederick, Maryland as a wholly owned subsidiary of International Stem Cell Corporation. Lifeline also supports researchers through scientist-led technical assistance and an international distributor network.FREDERICK, MD
Elk BioscienceElk Bioscience makes clinical-grade pooled human platelet lysate, a xeno-free cell-culture supplement for research, regenerative medicine and cell-therapy manufacturing. Based at the Pennsylvania Biotechnology Center in Doylestown, the company produces its hPL in a proprietary GMP facility using platelet units that would otherwise have been discarded, pooling material from more than 200 U.S. donors to reduce lot-to-lot variation. Its products are GMP compliant, heparin-free and supported by an FDA Data Master File for clinical-trial use.DOYLESTOWN, PA
BioFactura, IncFounded in Frederick in 2004, BioFactura develops and manufactures biosimilars, biodefense medical countermeasures, and other biologic medicines using its patented StableFast biomanufacturing platform. The clinical-stage company has advanced programs for a smallpox therapeutic and a proposed ustekinumab biosimilar, while its Capitol Biologics division provides development and early-phase clinical manufacturing support to emerging biotech firms and government agencies.FREDERICK, MD
MesoblastFounded in 2004 by physician-scientist Silviu Itescu, Mesoblast develops and manufactures allogeneic, off-the-shelf cellular medicines for severe inflammatory and tissue-damage conditions. Its proprietary mesenchymal lineage cell platform supports Ryoncil, the first FDA-approved mesenchymal stromal cell therapy, while the company advances additional therapies through operations in Australia, the United States and Singapore. Mesoblast’s manufacturing approach is designed for industrial-scale production of cryopreserved cell products without donor-recipient matching.NEW YORK, NY